VEENENDAAL, The Netherlands, May 14 /PRNewswire/ -- Nucletron, a knowledge-based leader in radiation oncology, today announced a new release of Oncentra(R) Brachy, a comprehensive film- and volume-based treatment planning system to optimize cancer treatment planning for brachytherapy. Oncentra Brachy, the world's first fully DICOM-compatible treatment planning system, is a user-friendly Windows-based planning system that features state-of-the-art optimization algorithms to ensure efficient treatment.
Oncentra Brachy is adaptable to any clinical workflow. As well as advanced 3D contouring and margining tools, Oncentra Brachy fully supports film-based (2D) treatment planning. The system allows for planning of a wide variety of brachytherapy treatments. Oncentra Brachy is fully geared up towards Intensity Modulated Brachytherapy (IMBT).
"We have set a new benchmark in brachytherapy treatment planning," said Jos Lamers, chief executive officer of Nucletron. "We have worked with our clinical partners to develop a solution that migrates PLATO users to a new platform that fits the demands of all clinics. As part of our full range of brachytherapy solutions, Oncentra Brachy is a key element of our efforts in improving patient care."
Nucletron will display and demonstrate Oncentra Brachy throughout the 2009 GEC ESTRO in Porto, Portugal, from 13 to 16 May 2009, and at ABS 2009 in Toronto, Canada, from 31 May to 2 June 2009.
Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.
|SOURCE Nucletron B V|
Copyright©2009 PR Newswire.
All rights reserved